0001140361-23-029888.txt : 20230614
0001140361-23-029888.hdr.sgml : 20230614
20230614182715
ACCESSION NUMBER: 0001140361-23-029888
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230613
FILED AS OF DATE: 20230614
DATE AS OF CHANGE: 20230614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Providenti Anthony C. Jr.
CENTRAL INDEX KEY: 0001765583
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22427
FILM NUMBER: 231015462
MAIL ADDRESS:
STREET 1: 3760 ROCKY MOUNTAIN AVENUE
CITY: LOVELAND
STATE: CO
ZIP: 80538
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HESKA CORP
CENTRAL INDEX KEY: 0001038133
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 770192527
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3760 ROCKY MOUNTAIN AVENUE
CITY: LOVELAND
STATE: CO
ZIP: 80538
BUSINESS PHONE: 9704937272
MAIL ADDRESS:
STREET 1: 3760 ROCKY MOUNTAIN AVENUE
CITY: LOVELAND
STATE: CO
ZIP: 80538
4
1
form4.xml
X0407
4
2023-06-13
true
0001038133
HESKA CORP
HSKA
0001765583
Providenti Anthony C. Jr.
3760 ROCKY MOUNTAIN AVENUE
LOVELAND
CO
80538
true
EVP, Corporate Development
false
Common Stock
2023-06-13
4
A
0
44456
0
A
63571
D
Common Stock
2023-06-13
4
A
0
4056
0
A
67627
D
Common Stock
2023-06-13
4
D
0
67627
120
D
0
D
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, these shares of performance-based restricted stock of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
Includes 396 shares of common stock of the Issuer purchased under the Issuer's employee stock purchase plan on May 26, 2023 and 11,000 shares of common stock of the Issuer originally reported as restricted stock.
Pursuant to the Merger Agreement, these performance-based restricted stock units were fully accelerated assuming target level of performance immediately prior to the effectiveness of the merger.
Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $120.00 per share of common stock of the Issuer on the effective date of the merger.
/s/ Catherine Grassman For: Anthony Providenti
2023-06-13